Skip to main content

BCR-ABL tyrosine kinase inhibitors

What are BCR-ABL tyrosine kinase inhibitors?

BCR-ABL tyrosine kinase inhibitors inhibit the enzyme BCR-ABL tyrosine kinase, which is important in the pathogenesis of chronic myelogenous leukemia (CML).

Chronic myelogenous leukemia occurs due a single genetic abnormality, known as the Philadelphia chromosome. During the translocation when the Philadelphia chromosome is created, a fusion gene called BCR-ABL gene is formed. The BCR-ABL gene encodes for the BCR-ABL tyrosine kinase. The BCR-ABL positive cells in chronic myelogenous leukemia have increased proliferation and resistance to cell death.

BCR-ABL tyrosine kinase inhibitors are used to treat chronic myelogenous leukemia.

List of BCR-ABL tyrosine kinase inhibitors

View by  Brand | Generic
Drug Name Avg. Rating Reviews
Gleevec (Pro)
Generic name: imatinib
35 reviews
Tasigna (Pro)
Generic name: nilotinib
30 reviews
Sprycel (Pro)
Generic name: dasatinib
21 reviews
Bosulif (Pro)
Generic name: bosutinib
6 reviews
Iclusig (Pro)
Generic name: ponatinib
2 reviews
Scemblix (Pro)
Generic name: asciminib
No reviews
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.